Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind Study to Assess the Safety and Efficacy of Mesalamine Delayed-release Capsules in Children Aged 5 to 17 Years for the Maintenance of Remission of Ulcerative Colitis

NCT05316220 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05316220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05316220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind Study to Assess the Safety and Efficacy of Mesalamine Delayed-release Capsules in Children Aged 5 to 17 Years for the Maintenance of Remission of Ulcerative Colitis
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Withdrawn
Start date
September 15, 2025
Completion date
July 19, 2026
Enrollment
0 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis (uc)